SightGlass Vision announced that, less than a year after the company surpassed 1 million wearers, 2 million children worldwide have now worn its DOT spectacle lenses, according to a press release.

DOT, or Diffusion Optics Technology, provides myopia control through contrast management. Specifically, the lenses are designed around research that examined differences in contrast levels between artificial and natural environments and their potential relationship with eye growth. The lenses incorporate thousands of elements that softly scatter light before it reaches the retina, with the aim of mimicking more natural contrast. The lenses first became commercially available in 2021 and have since launched in Canada, China, Israel, Spain, and the UK. However, they are not currently approved in the United States.

Additional market introductions are anticipated this year, and the company recently introduced its “Control the Contrast” professional education campaign to educate eyecare professionals about the underlying science.

In the press release, SightGlass Vision also highlighted new 2-year clinical data from its CATHAY study in China. Among children ages 6 to 10, DOT lenses resulted in more than 1.00 D less myopia progression on average after 2 years. Across the full study population of children ages 6 to 13, the lenses slowed average myopia progression by 67%, or 0.78 D, and average axial length progression by 62%, or 0.40 mm, compared with the control group after 2 years.

Teddy Chow of The Chow Eye Institute, an early adopter of DOT lenses in Canada, said in the press release that children in his practice have generally adapted easily to the lenses: Most no longer notice them within days and wear them as everyday glasses. He emphasized consistent wear as an important consideration when selecting a myopia-control treatment for a child.